• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients.

作者信息

Lamberg B A, Rantanen M, Saarinen P, Liewendahl K, Sivula A

出版信息

Acta Endocrinol (Copenh). 1979 Jun;91(2):248-56. doi: 10.1530/acta.0.0910248.

DOI:10.1530/acta.0.0910248
PMID:111446
Abstract

Absent response of serum thyrotrophin (TSH) after stimulation with 200 micrograms synthetic thyrotrophin-releasing hormone (TRH) was used as a criterion of adequate suppression of TSH in the treatment of thyroid carcinoma patients with thyroxine. The mean causing total suppression of the response was 223 micrograms of thyroxine per day. At this dose level about 40% of the patients had serum thyroxine concentrations above the upper reference interval and only 10% had elevated triiodothyronine concentrations. In some patients the TSH response to TRH varied between absent and low normal when tested at long intervals. The ideal dose of thyroxine is obviously slightly higher than the smallest one causing total suppression of the TSH response to TRH, i.e. about 250 micrograms a day. The individual dose must be found using the TRH stimulation test because serum thyroid hormone levels cannot be used as a guideline for adequate dosage. In some patients the thyroid remnant of apparently normal thyroid tissue was not totally suppressed although the thyroxine dose was definitely above the level causing suppression of the response to TRH.

摘要

相似文献

1
Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients.
Acta Endocrinol (Copenh). 1979 Jun;91(2):248-56. doi: 10.1530/acta.0.0910248.
2
Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy.接受甲状腺素治疗的甲状腺功能减退和甲状腺癌患者的游离甲状腺素、游离三碘甲状腺原氨酸和促甲状腺激素浓度。
Acta Endocrinol (Copenh). 1987 Nov;116(3):418-24. doi: 10.1530/acta.0.1160418.
3
Serum thyrotropin and prolactin in the syndrome of generalized resistance to thyroid hormone: responses to thyrotropin-releasing hormone stimulation and short term triiodothyronine suppression.全身性甲状腺激素抵抗综合征中的血清促甲状腺激素和催乳素:对促甲状腺激素释放激素刺激和短期三碘甲状腺原氨酸抑制的反应
J Clin Endocrinol Metab. 1990 May;70(5):1305-11. doi: 10.1210/jcem-70-5-1305.
4
[Evaluation of the optimal thyroxine dose with the TRH test for replacement and suppression therapy].[通过促甲状腺激素释放激素试验评估用于替代和抑制治疗的最佳甲状腺素剂量]
Schweiz Med Wochenschr. 1983 Dec 17;113(50):1922-3.
5
Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.对促甲状腺激素释放激素的反应:促甲状腺激素抑制治疗充分性的客观标准。
J Clin Endocrinol Metab. 1977 May;44(5):892-901. doi: 10.1210/jcem-44-5-892.
6
The thyrotrophin response to thyrotrophin releasing hormone during treatment in patients with Graves' disease.格雷夫斯病患者治疗期间促甲状腺激素对促甲状腺激素释放激素的反应。
Acta Endocrinol (Copenh). 1977 Jun;85(2):335-44. doi: 10.1530/acta.0.0850335.
7
TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.
J Clin Endocrinol Metab. 1976 May;42(5):901-6. doi: 10.1210/jcem-42-5-901.
8
Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.分化型甲状腺癌患者促甲状腺激素抑制治疗随访中促甲状腺激素的高灵敏度测定
Nuklearmedizin. 1988 Feb;27(1):24-8.
9
Thyroid vascular conductance: differential effects of elevated plasma thyrotropin (TSH) induced by treatment with thioamides or TSH-releasing hormone.甲状腺血管传导:硫代酰胺或促甲状腺激素释放激素治疗诱导的血浆促甲状腺激素(TSH)升高的不同影响。
Endocrinology. 1991 Jul;129(1):117-25. doi: 10.1210/endo-129-1-117.
10
Surveillance of TSH-suppressive levothyroxine treatment in thyroid cancer patients: TRH testing versus basal TSH determination by a third generation assay.甲状腺癌患者促甲状腺激素抑制性左甲状腺素治疗的监测:促甲状腺激素释放激素检测与第三代检测法测定基础促甲状腺激素
Exp Clin Endocrinol Diabetes. 2002 Oct;110(7):355-60. doi: 10.1055/s-2002-34993.

引用本文的文献

1
TSH suppression in the management of thyroid nodules and thyroid cancer.促甲状腺激素抑制在甲状腺结节和甲状腺癌管理中的应用
World J Surg. 1981 Jan;5(1):39-47. doi: 10.1007/BF01657832.
2
Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of an optimal saturation regimen with thyroxine or triiodothyronine.
J Endocrinol Invest. 1983 Dec;6(6):455-61. doi: 10.1007/BF03348345.
3
Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine.甲状腺癌患者全身扫描后促甲状腺激素抑制的不同速率:常规剂量甲状腺素和三碘甲状腺原氨酸的作用
J Endocrinol Invest. 1983 Feb;6(1):35-40. doi: 10.1007/BF03350558.
4
Nodular goiter: effects of surgery and thyroxine medication.
World J Surg. 1986 Jun;10(3):481-7. doi: 10.1007/BF01655315.
5
Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy.长期接受甲状腺素抑制治疗患者血清中甲状腺素被人肝癌细胞摄取的情况。
J Endocrinol Invest. 1988 Oct;11(9):629-35. doi: 10.1007/BF03350199.